Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial.

Research output: Contribution to journalArticle


Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity.


  • Henk van den Berg
  • Michael Paulussen
  • Gwénaël Le Teuff
  • Ian Judson
  • Hans Gelderblom
  • Uta Dirksen
  • Bernadette Brennan
  • Jeremy Whelan
  • Ruth Lydia Ladenstein
  • Perrine Marec-Berard
  • Jarmila Kruseova
  • Lars Hjorth
  • Thomas Kühne
  • Benedicte Brichard
  • Keith Wheatley
  • Alan Craft
  • Heribert Juergens
  • Nathalie Gaspar
  • Marie-Cécile Le Deley
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2453-2464
JournalEuropean Journal of Cancer
Issue number16
Publication statusPublished - 2015
Publication categoryResearch